Effect of Rifampicin on the Pharmacokinetics of Apatinib
The primary purpose of this study is to investigate potential pharmacokinetic interaction in healthy volunteers when apatinib is administered in combination with rifampicin. Secondary objective is evaluating the safety and tolerability of apatinib alone and when co-administered with rifampicin.
Neoplasms
DRUG: Apatinib Mesylate Tablets|DRUG: Rifampicin Capsules
Area under the plasma concentration versus time curve (AUC) of Apatinib, 0~72h after apatinib administration
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, From first administration to the seventh day after last administration|Peak Plasma Concentration (Cmax) of Apatinib, 0~72h after apatinib administration
The primary purpose of this study is to investigate potential pharmacokinetic interaction in healthy volunteers when apatinib is administered in combination with rifampicin. Secondary objective is evaluating the safety and tolerability of apatinib alone and when co-administered with rifampicin.